Bright Minds Biosciences (DRUG) Total Current Liabilities (2021 - 2026)

Bright Minds Biosciences has reported Total Current Liabilities for 6 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 528.6% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 528.6% YoY), and the FY2025 full-year result was $1.7 million, up 337.87% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.8 million, up from $1.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $2.8 million in Q1 2026, with the low at $209499.0 in Q3 2023.
• Historically, Total Current Liabilities has averaged $852827.6 across 5 years, with a median of $490603.7 in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities slumped 81.44% — and 2026, when it surged 528.6%.
• Bright Minds Biosciences' Total Current Liabilities stood at $389049.9 in 2022, then slumped by 46.15% to $209499.0 in 2023, then surged by 57.7% to $330380.1 in 2024, then soared by 243.49% to $1.1 million in 2025, then surged by 146.28% to $2.8 million in 2026.
• The last three Total Current Liabilities figures came in at $2.8 million (Q1 2026), $1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.